Vertex Pharmaceuticals Stock Forecast, Price & News

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

Is Vertex Pharmaceuticals a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks.

How has Vertex Pharmaceuticals' stock price been impacted by COVID-19?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRTX shares have increased by 6.2% and is now trading at $234.06.
View which stocks have been most impacted by COVID-19.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 7th 2022.
View our earnings forecast for Vertex Pharmaceuticals.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its earnings results on Tuesday, November, 2nd. The pharmaceutical company reported $3.56 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.74 by $0.82. The pharmaceutical company earned $1.98 billion during the quarter, compared to analyst estimates of $1.85 billion. Vertex Pharmaceuticals had a net margin of 30.52% and a trailing twelve-month return on equity of 31.03%. During the same period in the previous year, the firm posted $2.36 EPS.
View Vertex Pharmaceuticals' earnings history.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.40 billion-$7.50 billion, compared to the consensus revenue estimate of $7.32 billion.

What price target have analysts set for VRTX?

19 Wall Street analysts have issued 1-year price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $175.00 to $331.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $255.67 in the next year. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:

• Reshma Kewalramani, President, Chief Executive Officer & Director (LinkedIn Profile)
• Stuart A. Arbuckle, Chief Operating Officer & Executive Vice President
• Charles F. Wagner, Chief Financial Officer & Executive Vice President
• David Matthew Altshuler, Chief Scientific Officer & EVP-Global Research
• Mike Tirozzi, Senior VP, Chief Information & Data Officer

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

Who are some of Vertex Pharmaceuticals' key competitors?

Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Novavax (NVAX), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Arena Pharmaceuticals (ARNA).
View all of VRTX's competitors.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.36%), DNB Asset Management AS (0.19%), Scout Investments Inc. (0.10%), Cullinan Associates Inc. (0.04%), Gateway Investment Advisers LLC (0.04%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals.

Which institutional investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Moody National Bank Trust Division, DNB Asset Management AS, Gateway Investment Advisers LLC, Exchange Traded Concepts LLC, State of Alaska Department of Revenue, Wedbush Securities Inc., Diversified Trust Co, and McAdam LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Michael Parini, Paul M Silva, Sangeeta N Bhatia, and Stuart A Arbuckle.
View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Scout Investments Inc., Pensionfund Sabic, CHURCHILL MANAGEMENT Corp, First Hawaiian Bank, Valeo Financial Advisors LLC, Spire Wealth Management, and 17 Capital Partners LLC. Company insiders that have bought Vertex Pharmaceuticals stock in the last two years include Bruce I Sachs, and Reshma Kewalramani.
View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $234.06.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals has a market capitalization of $59.51 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $8.33 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals employs 3,400 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman II) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal) Unipessoal Lda., Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (Switzerland) Sàrl, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

Where are Vertex Pharmaceuticals' headquarters?

Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at [email protected], or via fax at 617-576-2109.